Allogeneic islet transplantation

Simona Marzorati, Antonello Pileggi, Camillo Ricordi

Research output: Contribution to journalReview articlepeer-review

36 Scopus citations


Significant progress has been made in the field of β-cell replacement therapies by islet transplantation in patients with unstable Type 1 diabetes mellitus (T1DM). Recent clinical trials have shown that islet transplantation can reproducibly lead to insulin independence when adequate islet numbers are implanted. Benefits include improvement of glycemic control, prevention of severe hypoglycemia and amelioration of quality of life. Numerous challenges still limit this therapeutic option from becoming the treatment of choice for T1DM. The limitations are primarily associated with the low islet yield of human pancreas isolations and the need for chronic immunosuppressive therapies. Herein the authors present an overview of the historical progress of islet transplantation and outline the recent advances of the field. Cellular therapies offer the potential for a cure for patients with T1DM. The progress in β-cell replacement treatment by islet transplantation as well as those of emerging immune interventions for the restoration of self tolerance justify great optimism for years to come.

Original languageEnglish (US)
Pages (from-to)1627-1645
Number of pages19
JournalExpert Opinion on Biological Therapy
Issue number11
StatePublished - Nov 2007


  • β-cells
  • Clinical trials
  • Insulin independence
  • Islet transplantation
  • Type 1 diabetes

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology


Dive into the research topics of 'Allogeneic islet transplantation'. Together they form a unique fingerprint.

Cite this